Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Roberts, Richard E. (2012)
Publisher: Dove Press
Journal: Journal of Experimental Pharmacology
Languages: English
Types: Article
Subjects: Review, smooth muscle, vasoconstriction, hypertension, Journal of Experimental Pharmacology, ERK
Richard E RobertsSchool of Biomedical Sciences, University of Nottingham, Nottingham, United KingdomAbstract: Hypertension is a risk factor for myocardial infarction, stroke, renal failure, heart failure, and peripheral vascular disease. One feature of hypertension is a hyperresponsiveness to contractile agents, and inhibition of vasoconstriction forms the basis of some of the treatments for hypertension. Hypertension is also associated with an increase in the growth and proliferation of vascular smooth muscle cells, which can lead to a thickening of the smooth muscle layer of the blood vessels and a reduction in lumen diameter. Targeting both the enhanced contractile responses, and the increased vascular smooth muscle cell growth could potentially be an important pharmacological treatment of hypertension. Extracellular signal-regulated kinase (ERK) is a member of the mitogen-activated protein kinase family that is involved in both vasoconstriction and vascular smooth muscle cell growth and this, therefore, makes it an attractive therapeutic target for treatment of hypertension. ERK activity is raised in vascular smooth muscle cells from animal models of hypertension, and inhibition of ERK activation reduces both vascular smooth muscle cell growth and vasoconstriction. This review discusses the potential for targeting ERK activity in the treatment of hypertension.Keywords: ERK, hypertension, smooth muscle, vasoconstriction
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75(1):50-83.
    • 2. Cobb MH. MAP kinase pathways. Prog Biophys Mol Biol. 1999;71(3-4): 479-500.
    • 3. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007;26(22):3100-3112.
    • 4. Hawes BE, Luttrell LM, van Biesen T, Lefkowitz RJ. Phosphatidylinositol 3-kinase is an early intermediate in the Gβγ-mediated mitogen-activated protein kinase signaling pathway. J Biol Chem. 1996;271(21):12133-12136.
    • 5. YamanakaY, Hayashi K, Komurasaki T, Morimoto S, Ogihara T, Sobue K. EGF family ligand-dependent phenotypic modulation of smooth muscle cells through EGF receptor. Biochem Biophys Res Commun. 2001; 281(2):373-377.
    • 6. Eguchi S, Numaguchi K, Iwasaki H, et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin IIinduced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem. 1998;273(15):8890-8896.
    • 7. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of Erk and p38 MAPK but not for JNK. J Biol Chem. 2001; 276(11):7957-7962.
    • 8. Gao Y, Tang S, Zhou S, Ware A. The thromboxane A2 receptor activates mitogen-activated protein kinase via protein kinase C-dependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor. J Pharmacol Exp Ther. 2001;296(2):426-433.
    • 9. Zwick E, Hackel PO, Prenzel N, Ullrich A. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci. 1999;20(10):408-412.
    • 10. Lais LT, Brody MJ. Mechanism of vascular hyperresponsiveness in the spontaneously hypertensive rat. Circ Res. 1975;36(6 Suppl 1): 216-222.
    • 11. Bruner CA. Vascular responsiveness in rats resistant to aldosterone-salt hypertension. Hypertension. 1992;20(1):59-66.
    • 12. Dessy C, Kim I, Sougnez CL, Laporte R, Morgan KG. A role for MAP kinase in differentiated smooth muscle contraction evoked by α-adrenoceptor stimulation. Am J Physiol. 1998;275(4 Pt 1): C1081-C1086.
    • 13. Banes A, Florian JA, Watts SW. Mechanisms of 5-hydroxytryptamine2A receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther. 1999;291(3): 1179-1187.
    • 14. Roberts RE. Role of the extracellular signal-regulated kinase (ERK) signal transduction cascade in α2-adrenoceptor-mediated vasoconstriction in porcine palmar lateral vein. Br J Pharmacol. 2001; 133(6):859-866.
    • 15. Oeckler RA, Kaminski PM, Wolin MS. Stretch enhances contraction of bovine coronary arteries via an NADPH oxidase-mediated activation of the extracellular signal-regulated mitogen-activated protein kinase cascade. Circ Res. 2003;92(1):23-31.
    • 16. Ngai PK, Walsh MP. Inhibition of smooth muscle actin-activated myosin Mg2+ ATPase activity by caldesmon. J Biol Chem. 1984; 259(22):13656-13659.
    • 17. Adam LP, Hathaway DR. Identification of mitogen-activated protein kinase phosphorylation sequences in mammalian h-caldesmon. FEBS Lett. 1993;322(1):56-60.
    • 18. Patchell VB, Vorotnikov AV, Gao Y, et al. Phosphorylation of the minimal inhibitory region at the C-terminus of caldesmon alters its structural and actin binding properties. Biochim Biophys Acta. 2002; 1596(1):121-130.
    • 19. Xiao DL, Pearce WJ, Longo LD, Zhang L. ERK-mediated uterine artery contraction: role of thick and thin filament regulatory pathways. Am J Physiol Heart Circ Physiol. 2004;286(5):H1615-H1622.
    • 20. D'Angelo G, Graceffa P, Wang CA, Wrangle J, Adam LP. Mammalspecif ic, ERK-dependent, caldesmon phosphorylation in smooth muscle. Quantitation using novel anti-phosphopeptide antibodies. J Biol Chem. 1999;274(42):30115-30121.
    • 21. Yokouchi K, Numaguchi Y, Kubota R, et al. l-caldesmon regulates proliferation and migration of vascular smooth muscle cells and inhibits neointimal formation after angioplasty. Arterioscler Thromb Vasc Biol. 2006;26(10):2231-2237.
    • 22. Gorenne I, Su X, Moreland RS. Inhibition of p42 and p44 MAP kinase does not alter smooth muscle contraction in swine carotid artery. Am J Physiol. 1998;275(1 Pt 2):H131-H138.
    • 23. Hedges JC, Oxhorn BC, Carty M, Adam LP, Yamboliev IA, Gerthoffer WT. Phosphorylation of caldesmon by ERK MAP kinases in smooth muscle. Am J Physiol Cell Physiol. 2000;278(4):C718-C726.
    • 24. Childs TJ, Watson MH, Sanghera JS, Campbell DL, Pelech SL, MakAS. Phosphorylation of smooth muscle caldesmon by mitogen-activated protein (MAP) kinase and expression of MAP kinase in differentiated smooth muscle cells. J Biol Chem. 1992;267(32):22853-22859.
    • 25. Nixon GF, Iizuka K, Haystead CM, Haystead TA, Somlyo AP, Somlyo AV. Phosphorylation of caldesmon by mitogen-activated protein kinase with no effect on Ca2+ sensitivity in rabbit smooth muscle. J Physiol. 1995;487(Pt 2):283-289.
    • 26. Klemke RL, Cai S, GianniniAL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol. 1997;137(2):481-492.
    • 27. Roberts RE. The role of Rho kinase and extracellular regulated kinase-mitogen-activated protein kinase in α2-adrenoceptor-mediated vasoconstriction in the porcine palmar lateral vein. J Pharmacol Exp Ther. 2004;311(2):742-747.
    • 28. Escano CS Jr, Keever LB, Gutweiler AA, Andresen BT. Angiotensin II activates extracellular signal-regulated kinase independently of receptor tyrosine kinases in renal smooth muscle cells: implications for blood pressure regulation. J Pharmacol Exp Ther. 2008;324(1):34-42.
    • 29. Mulvany MJ, Hansen OK, Aalkjaer C. Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ Res. 1978;43(6):854-864.
    • 30. Mii S, Khalil RA, Morgan KG, Ware JA, Kent KC. Mitogen-activated protein kinase and proliferation of human vascular smooth muscle cells. Am J Physiol. 1996;270(1 Pt 2):H142-H150.
    • 31. Wilden PA, Agazie YM, Kaufman R, Halenda SP. ATP-stimulated smooth muscle cell proliferation requires independent ERK and PI3K signaling pathways. Am J Physiol. 1998;275(4 Pt 2):H1209-H1215.
    • 32. Yu SM, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation. 1997;95(5): 1269-1277.
    • 33. Zhang H, Chalothorn D, Jackson LF, Lee DC, Faber JE. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ Res. 2004;95(10):989-997.
    • 34. Liu G, Hitomi H, Hosomi N, et al. Mechanical stretch potentiates angiotensin II-induced proliferation in spontaneously hypertensive rat vascular smooth muscle cells. Hypertens Res. 2010;33(12):1250-1257.
    • 35. Roy J, Kazi M, Hedin U, Thyberg J. Phenotypic modulation of arterial smooth muscle cells is associated with prolonged activation of ERK1/2. Differentiation. 2001;67(1-2):50-58.
    • 36. Mulvany MJ, Baandrup U, Gundersen HJ. Evidence for hyperplasia in mesenteric resistance vessels of spontaneously hypertensive rats using a three-dimensional dissector. Circ Res. 1985;57(5):794-800.
    • 37. Rizzoni D, Porteri E, Guefi D, et al. Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension. 2000;35(4):931-935.
    • 38. Kida T, Chuma H, Murata T, et al. Chronic treatment with PDGF-BB and endothelin-1 synergistically induces vascular hyperplasia and loss of contractility in organ-cultured rat tail artery. Atherosclerosis. 2011; 214(2):288-294.
    • 39. Kim S, Murakami T, Izumi Y, et al. Extracellular signal-regulated kinase and c-Jun NH2-terminal kinase activities are continuously and differentially increased in aorta of hypertensive rats. Biochem Biophys Res Commun. 1997;236(1):199-204.
    • 40. Touyz RM, Deschepper C, Park JB, et al. Inhibition of mitogen-activated protein/extracellular signal-regulated kinase improves endothelial function and attenuates Ang II-induced contractility of mesenteric resistance arteries from spontaneously hypertensive rats. J Hypertens. 2002;20(6):1127-1134.
    • 41. Kim J, Lee YR, Lee CH, et al. Mitogen-activated protein kinase contributes to elevated basal tone in aortic smooth muscle from hypertensive rats. Eur J Pharmacol. 2005;514(2-3):209-215.
    • 42. Touyz RM, He G, El Mabrouk M, Diep Q, Mardigyan V, Schiffrin EL. Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats. J Hypertens. 2001;19(3 Pt 2):553-559.
    • 43. Kubo T, Ibusuki T, Chiba S, Kambe T, Fukumori R. Altered mitogenactivated protein kinase activation in vascular smooth muscle cells from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2002; 29(7):537-543.
    • 44. Tabet F, Schiffrin EL, Callera GE, et al. Redox-sensitive signalling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res. 2008;103(2):149-158.
    • 45. Touyz RM, El Mabrouk M, He G, Wu XH, Schiffrin EL. Mitogenactivated protein extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ Res. 1999;84(5): 505-515.
    • 46. Jing L, Zhang J, Sun J, et al. Inhibition of extracellular signal-regulated kinases ameliorates hypertension-induced renal vascular remodeling in rat models. Int J Mol Sci. 2011;12(12):8333-8346.
    • 47. Muthalif MM, Benter IF, Khandekar Z, et al. Contribution of Ras GTPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension. Hypertension. 2000;35(1 Pt 2): 457-463.
    • 48. Muthalif MM, Karzoun NA, Gaber L, et al. Angiotensin II-induced hypertension: contribution of Ras GTPase/mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension. 2000;36(4): 604-609.
    • 49. Ren Y, D'Ambrosio MA, Liu R, Pagano PJ, Garvin JL, Carretero OA. Enhanced myogenic response in the afferent arteriole of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2010;298(6): H1769-H1775.
    • 50. Budzyn K, Ravi RM, Miller AA, Sobey CG. Mechanisms of augmented vasoconstriction induced by 5-hydroxytryptamine in aortic rings from spontaneously hypertensive rats. Br J Pharmacol. 2008;155(2): 210-216.
    • 51. Cruzado MC, Risler NR, Miatello RM, Yao G, Schiffrin EL, Touyz RM. Vascular smooth muscle cell NADPH oxidase activity during the development of hypertension: effect of angiotensin II and role of insulin-like growth factor-1 receptor transactivation. Am J Hypertens. 2005;18(1):81-87.
    • 52. Zhang A, Jia Z, Wang N, Tidwell TJ, Yang T. Relative contribution of mitochondria and NADPH oxidase to deoxycorticosterone acetate-salt hypertension in mice. Kidney Int. 2011;80(1):51-60.
    • 53. Tabet F, Schiffrin EL, Touyz RM. Mitogen-activated protein kinase activation by hydrogen peroxide is mediated through tyrosine kinasedependent, protein kinase C-independent pathways in vascular smooth muscle cells: upregulation in spontaneously hypertensive rats. J Hypertens. 2005;23(11):2005-2012.
    • 54. Lee SL, Wang WW, Finlay GA, Fanburg BL. Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am J Physiol. 1999;277(2 Pt 1):L282-L291.
    • 55. Lee SL, Wang WW, Fanburg BL. Superoxide as an intermediate signal for serotonin-induced mitogenesis. Free Radic Biol Med. 1998;24(5): 855-858.
    • 56. Blanc A, Pandey NR, Srivastava AK. Distinct roles of Ca2+, calmodulin, and protein kinase C in H2O2-induced activation of ERK1/2, p38 MAPK, and protein kinase B signaling in vascular smooth muscle cells. Antioidx Redox Signal. 2004;6(2):353-366.
    • 57. Adachi T, Pimentel DR, Heibeck T, et al. S-glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells. J Biol Chem. 2004;279(28):29857-29862.
    • 58. Lane KT, Beese LS. Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res. 2006;47(4):681-699.
    • 59. Tristano AG, Castejon AM, Castro A, Cubeddu LX. Effects of statin treatment and withdrawal on angiotensin II-induced phosphorylation of p38 MAPK and ERK1/2 in cultured vascular smooth muscle cells. Biochem Biophys Res Commun. 2007;353(1):11-17.
    • 60. Negre-AminouP,vanVlietAK,vanErckM,vanThielGC,vanLeeuwenRE, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta. 1997;1345(3):259-268.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article